Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes

HealthPartners Institute124 enrolled

Overview

The purpose of this study is to evaluate the use of SMBG and CGM for clinical decisions related to the management of type 2 diabetes. The secondary objective is to determine the benefit of using CGM for clinical diabetes management decision-making.

This study involves the use of the following 2 glucose monitoring methods to measure your blood sugar (glucose) levels and help manage type 2 diabetes: 1. Self Monitoring Blood Glucose (SMBG): blood glucose is measured 4-7 times each day using finger sticks and an blood glucose meter. 2. Continuous Glucose Monitoring (CGM): blood glucose is measured continuously via the CGM device. This device has been approved for use by the U.S. Food and Drug Administration (FDA).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

124

Conditions

Type 2 Diabetes

Interventions

CGM GroupDEVICE

Using CGM unblinded for 16 weeks versus fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes.

SMBG GroupDEVICE

Fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes. Used CGM blinded once every four weeks.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female ≥18 and ≤75 years of age (Upper range to assure dexterity for use of CGM) * Clinical diagnosis of type 2 diabetes * HbA1c ≥7.0% * Diabetes can be treated with any of the following therapies within one month prior to study enrollment: (1) medical nutrition therapy alone or with metformin; (2) sulfonylurea with or without metformin; (3) dipeptidyl peptidase 4 (DPP-4) inhibitor or Glucagon-like peptide-1 (GLP-1) agonist with or without metformin; or insulin with or without metformin. Exclusion Criteria: * Treated with Thiazolidinediones (TZD) * Administered prednisone or cortisone medications in the previous 30 days * Currently pregnant or planning pregnancy during the study period * Presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study * HbA1c \<7.0% * Unable to follow the study protocol * Unable to speak, read and write in English

Locations (1)

International Diabetes Center

Minneapolis, Minnesota, United States

Outcomes

Primary Outcomes

Percentage Change in Hemoglobin A1c

Time frame: 2 week baseline to 16 week final

Secondary Outcomes

Glucose Exposure (Area Under the Diurnal Median Curve)

The secondary objective is to determine the incremental benefit of CGM for clinical decision-making by using (area under the diurnal median curve). Data was collected to create the curve at every hour of modal day. Example: hours 1-24 of each day. Modal day reflects 14 days worth of CGM data aggregated into a single 24 hour day graph.

Time frame: 16 weeks

Percent of Time in Hypoglycemia Range

The secondary objective is to determine the incremental benefit of CGM for clinical decision-making using percent time in hypoglycemia range (\< 50 mg/dL). Numerator: amount of time with a value of 49 mg/dL or less. Denominator: total amount of time of CGM measurement. CGM used for this study produced measurements once every 15 minutes or 360 times per day.

Time frame: 16 weeks

Change From Baseline in CGM Glucose Variability

Glucose Variability - Interquartile Range used to determine incremental benefit of CGM for clinical decision making. IQR results reflect the change delta from baseline to 16 weeks. IQR is calculated for each subject at each visit. The change in IQR was calculated as final IQR minus baseline IQR. This measure represents an average of the individual subjects IQR delta (baseline to 16 weeks/final).

Time frame: Baseline and 16 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.